Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963439 | 0.75 | GSK3B (0.41) | ELANENPC1ALDH1A1MAPTHPGD | |
| SCHEMBL7775891 | 0.75 | CA2 (0.61) | ELANECA2 | |
| SCHEMBL21963465 | 0.74 | RAB9A (0.40) | NPC1ALDH1A1TP53MAPTHPGD | |
| SCHEMBL4515919 | 0.73 | RAB9A (0.55) | NPC1ALDH1A1TP53MAPTHPGD | |
| SCHEMBL14911794 | 0.71 | GSK3B (0.56) | ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL13998362 | 0.69 | ELANE (0.76) | ELANEHSD17B10 | |
| SCHEMBL21963440 | 0.68 | PTP4A3 (0.58) | ELANECA2 | |
| SCHEMBL21963442 | 0.68 | CDC7 (0.57) | ELANECA2MEN1KMT2A | |
| SCHEMBL22369614 | 0.67 | ELANE (0.86) | ELANE | |
| SCHEMBL17369683 | 0.66 | HDAC3 (0.59) | ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3880684-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880200-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102245-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102243-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRC, PTPRF | ELANE 4296/4885NPC1 4780/4885ALDH1A1 1620/4885 |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | PTP4A3, PTPRO, PTPRC | ELANE 3973/4885NPC1 4770/4885ALDH1A1 1667/4885 |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRO, PTPRC | ELANE 4102/4885NPC1 4784/4885ALDH1A1 1488/4885 |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | PTP4A3, PTPRC, PTPRF | ELANE 4296/4885NPC1 4780/4885ALDH1A1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.